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ABSTRACT
The DNA glycosylase gene MBD4 safeguards genomic stability at CpG sites and 
is frequently mutated at coding poly-A tracks in mismatch repair (MMR)-defective 
colorectal tumors (CRC). Mbd4 biallelic inactivation in mice provided conflicting results 
as to its role in tumorigenesis. Thus, it is unclear whether MBD4 alterations are only 
secondary to MMR defects without functional consequences or can contribute to the 
mutator phenotype. We investigated MBD4 variants in a large series of hereditary/
familial and sporadic CRC cases. Whereas MBD4 frameshifts were only detected 
in tumors, missense variants were found in both normal and tumor DNA. In CRC 
with double-MBD4/MMR and single-MBD4 variants, transition mutation frequency 
was increased, indicating that MBD4 defects may affect the mutational landscape 
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independently of MMR defect. Mbd4-deficient mice showed reduced survival when 
combined with Mlh1−/− genotype. Taken together, these data suggest that MBD4 
inactivation may contribute to tumorigenesis, acting as a modifier of MMR-deficient 
cancer phenotype.
INTRODUCTION
MBD4, also known as MED1, is a methylcytosine 
binding domain (MBD)-containing, base excision 
repair (BER) thymine (T) and uracil (U) glycosylase 
that prevents mutability at CpG sites by removing T 
and U from G:T and G:U mismatches arising from 
spontaneous deamination of 5-methylcytosine (5mC) and 
cytosine (C), respectively [1–4]. Remarkably, MBD4 is 
also a binding partner of the mismatch repair (MMR) 
protein MLH1 and modulates the levels of core MMR 
proteins [2, 5]. In addition to its roles in genomic stability, 
MBD4 is a multifunctional protein involved in several 
cellular processes [6], including apoptotic response 
to DNA damage [5, 7], transcriptional repression [8], 
chromosomal stability [9] and Immunoglobulin Class 
Switch Recombination (CSR) [10]. More recently, a role 
of MBD4 in active DNA demethylation has been proposed 
but remains controversial [11–14].
Several studies focused on the role of alterations 
of the MBD4 gene in tumorigenesis. MBD4 is frequently 
mutated (20–45%) in hereditary and sporadic colorectal 
cancer (CRC) cases with MMR defects and consequent 
microsatellite instability (MSI) [15–18]. Moreover, a 
similar fraction of human endometrial, pancreatic and 
gastric carcinomas with microsatellite instability (MSI) 
also show MBD4 mutations [17–21]. The majority of 
MBD4 sequence variants found in these tumors are 
frameshift mutations that affect A6 and A10 polyadenine 
tracks in the coding region, leading to truncated MBD4 
proteins that lack the glycosylase domain [15–19]. It has 
been proposed that these truncated MBD4 proteins lack 
the ability to bind MLH1 and may act in a dominant 
negative fashion, inhibiting the glycosylase activity of 
the wild type protein expressed from the unaffected 
allele [9, 22]. On the other hand, alternative mechanisms 
of biallelic MBD4 inactivation have been described: in 
CRC frameshift mutations were accompanied by loss of 
heterozygosity (LOH) of the wild type allele [17]; and 
silencing of MBD4 by promoter hypermethylation can 
occur in CRC and ovarian cancer [23]. An association 
between MBD4 expression changes and DNA sequence 
variants has also been found in a fraction of hepatocellular 
carcinomas, brain tumors, esophageal squamous cell 
carcinomas and urothelial cell carcinomas [24–27].
Recently, in next-generation sequencing studies, 
MBD4 somatic alterations, including point mutations 
and amplifications/deletions, have been identified, at a 
frequency ranging between 0.5%-8%, in a large series of 
unselected tumor samples (i.e. melanoma, ovarian, lung, 
esophagus and prostate cancers) [28–30]. However, it 
is still unclear whether MBD4 alterations are due to the 
genomic instability, e.g. are secondary to a MMR defect 
without having functional consequences on the tumor 
mutational landscape, or can contribute to the mutator 
phenotype separately from the MMR defect, conferring a 
growth advantage to cancer cells.
Mouse studies have only partially clarified this 
issue. Biallelic inactivation of Mbd4 alone does not 
initiate tumorigenesis in the mouse nor does it cause [31]. 
However, homozygous loss of Mbd4 increases the 
frequency of C > T transition mutations at CpG sites and 
accelerates tumorigenesis in the Adenomatous Polyposis 
Coli (Apc) cancer-predisposing background [31, 32]. 
These results provide evidence that MBD4 functions 
in vivo to suppress mutations at CpG sites in mammalian 
genomes, and that its loss, while insufficient to initiate 
tumorigenesis by itself, can promote tumor formation 
in the context of a cancer-predisposing background. 
This contention was challenged by another study in 
which biallelic inactivation of Mbd4 had no impact on 
mutation  frequency and tumorigenesis in MMR-deficient 
tumors [33].
Thus, the role of MBD4 in MMR-deficient 
tumorigenesis, which is precisely the situation in which 
most MBD4 mutations in human cancer occur, is still 
a matter under debate. In order to elucidate the role of 
MBD4 in colorectal tumorigenesis, we conducted a 
combined human-mouse study: we assessed the frequency, 
pattern and significance of germline and somatic MBD4 
mutations in a series of human CRC patients and tumors, 
respectively, and tested whether biallelic inactivation of 
Mbd4 in a murine model may affect tumorigenesis and/
or modify the tumor-predisposing phenotype on a cancer 
susceptible Mlh1−/− background.
RESULTS
Frequency and pattern of MBD4 sequence 
variants
To investigate the role of MBD4 in tumorigenesis 
and the interaction between MBD4 and MMR genes, 
sequence analysis of the entire coding region of MBD4 
was performed in a total of 332 CRC cases, including 
259 hereditary (i.e., meeting the Amsterdam/Bethesda 
criteria) or familial cases (partially fulfilling the 
Amsterdam/Bethesda criteria) and 73 sporadic cases. 
MBD4 mutational analysis was initially conducted on 41 
MMR-deficient MSI tumors, of which 17 were hereditary/
familial and 24 were sporadic tumors. In terms of type of 
sequence change, frameshift mutations in coding A6 or A10 
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tracks were detected in hereditary/familial (8/17, 47.1%) 
and sporadic tumors (9/24, 37.5%), whereas one particular 
missense variant (p.Ala273Pro) was identified in 2/17 
(11.8%) hereditary/familial and 1/24 (4.2%) sporadic 
tumors, respectively (Table 1).
We next investigated MBD4 sequence variants in the 
germline of hereditary/familial and sporadic CRC cases. 
While no germline frameshift changes were identified, 
MBD4 missense variants were found in 11/242 (4.5%) 
hereditary/familial and 6/49 (12.2%) sporadic patients, 
respectively (Table 2). According to tumor MSI status, 
the patients on which germline sequence analysis was 
conducted were divided in three groups: i) MSI-H 
(n = 61); ii) MSS/MSI-L (n = 111); and iii) unknown MSI 
status (n = 119). Germline MBD4 missense variants were 
present in MSI-H (8/61, 13.1%), MSS/MSI-L (4/111, 
3.6%) and unknown MSI cases (5/119, 4.2%) (Table 2).
Overall, we found a total of 8 germline/somatic 
MBD4 missense variants in 20 patients/tumors, of 
which 2 missense variants (p.Cys386Phe, p.Thr463Ser) 
were identified for the first time in this study (Fig. 1) 
(Table 3). Co-occurrence of MBD4 variants (frameshift 
or missense changes) with MMR mutations was found 
in 17/332 (5.1%) total patients/tumors, and in 28/102 
(27.4%) of MSI-H patients (Table 2)/tumors (Table 1). 
Germline and somatic p.Ala273Pro variant was found 
associated with MMR defects in 3 patients and 2 tumors, 
respectively; of these five cases, two were associated 
with MLH1 pathogenic mutations, two with MSH2 
pathogenic mutations and one with a MSH6 variant of 
unknown significance (Table 3). Co-occurrence of MLH1 
pathogenic mutations (8 germline and 1 somatic) and the 
recurrent MBD4 frameshift mutations in coding A6 or A10 
tracks were identified in 9 tumors. The MBD4 variants 
p.Asp568His and p.Cys386Phe were found in MLH1-
deficient tumors, and the MBD4 p.Ser342Pro variant 
was found in a MSH2-deficient tumor. No co-occurrence 
with MMR defects was observed for the remaining 
MBD4 variants (p.Glu346Lys, p.Ile358Thr, p.Thr463Ser, 
p.Asn467Ser) (Table 3).
For twenty cases, matched normal and tumor DNA 
was available, allowing us to conduct LOH studies with 
markers D3S3606, D3S1587 and D3S1290 at the MBD4 
locus (3q21-22), as previously described [17]. Out of 
six tumors found to exhibit LOH at 3q21–22, three 
tumors displayed a frameshift mutation at the A10 track 
(Suppl. Fig. 1).
Functional and in silico assays of MBD4 missense 
variants
To gain insight into the functional consequences 
of the MBD4 missense variant p.Thr463Ser and 
p.Asp568His located in the glycosylase domain, we 
carried out in vitro glycosylase assays to assess the rate of 
thymine removal from double-stranded DNA containing 
a G:T mismatch. Wild type MBD4, p.Thr463Ser and 
p.Asp568His mutant proteins, as well as two additional 
Table 1: Frequency of somatic (tumor) MBD4 variants according to clinical and molecular pathology data1
Type of MBD4 sequence 
changes
Total number of tumors 
with MBD4 variants 
(n = 20)
Frequency of MBD4 
variants in Hereditary/
Familial CRC2 (n = 17)
Frequency of MBD4 
variants in Sporadic CRC 
(n = 24)
Missense 3 2/17 1/24
Frameshift mutation in 
coding A6 or A10 tracks
17 8/17 9/24
1All the tumors included in this Table are MSI-H.
2This group includes hereditary (fulfilling the Amsterdam or Bethesda criteria) and familial CRC cases (familial 
aggregation, partially fulfilling the Amsterdam or Bethesda criteria).
Table 2: Frequency of germline missense MBD4 variants according to clinical and molecular pathology data
Total number of cases 
with MBD4 variants
Frequency of 
MBD4 variants in 
Hereditary/Familial 
CRC1 (n = 242)
Frequency of 
MBD4 variants 
in Sporadic 
CRC (n = 49)
Frequency of 
MBD4 variants 
in CRC with 
MSI-H (n = 61)
Frequency of 
MBD4 variants 
in CRC with 
MSS/MSI-L 
(n = 111)
Frequency of 
MBD4 variants 
in CRC with 
unknown MSI 
status (n = 119)
17 11/242 6/49 8/61 4/111 5/119
1This group includes hereditary (fulfilling the Amsterdam or Bethesda criteria) and familial CRC cases (familial 
aggregation, partially fulfilling the Amsterdam or Bethesda criteria).
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missense variants (p.Ser342Pro and p.Cys386Phe) not 
located in the glycosylase domain were tested. Compared 
with the wild type protein, only the mutant protein 
p.Thr463Ser showed a significant reduction in the rate of 
thymine removal from the G:T substrate (approximately 
18% of wild type protein). Moreover, the p.Ser342Pro and 
p.Cys386Phe mutant proteins showed slightly reduced 
glycosylase activity (approximately 37% of wild type 
protein) (Fig. 2).
In silico analysis was also performed to predict the 
pathogenic role of the coding variants identified in this 
study. Three out of four programs predicted a possible 
impact of p.Cys386Phe and p.Thr463Ser amino acid 
substitutions on MBD4 function and a non-pathogenic role 
for p.Glu346Lys. Conversely, they concordantly predicted 
a non-pathogenic role for p.Ala273Pro, p.Ser342Pro 
and p.Ile358Thr variants. Discordant predictions were 
obtained for the two remaining variants, p.Asn467Ser 
and p.Asp568His. In addition, p.Ala273Pro, p.Ser342Pro, 
p.Glu346Lys, p.Ile358Thr, p.Asn467Ser and p.Asp568His 
were found in control populations (Table 3).
Although the in silico analysis predicted that 
p.Ala273Pro, p.Ser342Pro and p.Glu346Lys would not 
affect MBD4 protein function, it is possible that they could 
alter the interaction of MBD4 with Sin3A and HDAC1 
proteins, which bind within this region [8] (Table 3).
In order to test the hypothesis that MBD4 alterations 
are not only secondary to MSI in MMR-deficient 
tumors and may be selected for during tumorigenesis, 
we evaluated the frequency of pathogenic and likely 
non-pathogenic MBD4 variants, as determined by in 
silico prediction, in a cohort of unselected CRC cases 
(n = 1536), from COSMIC and cBioPortal databases, 
and control samples (n = 6503), from the Exome Variant 
Server (http://evs.gs.washington.edu/EVS/). Pathogenic 
MBD4 variants were found in 13/1536 (0.85%) and 
10/6503 (0.15%) CRC cases and controls, respectively; 
likely non-pathogenic variants were present in 21/1536 
(1.37%) and 24/6503 (0.37%) CRC cases and controls, 
respectively. A test of association between pathogenic 
MBD4 variants and presence of tumor was highly 
significant (Fisher’s exact test p-value <0.0001). 
Moreover, a binomial test of proportions between the 
frequency of MBD4 pathogenic and likely non-pathogenic 
variants in tumor and control samples was also significant 
(p-value < 0.0001).
Higher frequency of transition mutations in 
CRC tumors with MBD4 variants
Because an MBD4 defect is expected to lead to 
C:G > T:A transition mutations in the context of CpG 
sites [3], we analyzed the data deposited in the COSMIC 
database v72 [34] to investigate the average number of C:G 
> T:A transitions in CRC tumors with MBD4 pathogenic 
(frameshift) variants, MLH1 pathogenic variants or 
combined MBD4 plus major MMR gene variants (MLH1, 
MSH2 and MSH6) and, as controls, CRC tumors with no 
MBD4 or major MMR gene variants. We found that the 
average number of C:G > T:A transitions in CRC with 
combined MBD4 plus major MMR gene variants, CRC 
with MBD4 variants, and CRC with MLH1 variants was 35, 
31.4 and 10.6 times higher than control tumors, respectively 
(Fig. 3). Although this analysis is not limited to CpG 
sites and may reflect an overall increase in the transition 
load, these observations suggest that MBD4 variants may 
modify the pattern of somatic mutations in CRC, i.e. act as 
transition mutators, separately from MMR defects.
Figure 1: Schematic illustration of MBD4 gene, showing the main known functional and putative domains, and 
location of the identified DNA variants in this study. The novel variants identified in this study are reported in bold. The recurrent 
frameshift mutations (p.Lys248fs and p.Val310fs) are located in coding A6 and A10 tracks.
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Deficiency of Mbd4 leads to accelerated 
tumorigenesis in Mlh1−/− mice
In order to better characterize the in vivo role of 
biallelic inactivation of Mbd4 in the context of MMR-
deficient tumorigenesis, we generated Mbd4- Mlh1- double 
knock-out mice. A total of 178 mice were divided into four 
cohorts: Mbd4−/− Mlhl−/−, Mbd4+/+ Mlhl−/−, Mbd4−/− Mlhl+/+ 
and a cohort of wild type, single or double heterozygotes 
together. Mice were aged and monitored for lymphoma 
development, which is the predominant tumor type in this 
Mlh1-mutant strain [35]. Mbd4 deficiency conferred a 
significant survival reduction in Mbd4−/− Mlh1−/− double 
knock-out mice compared with Mlh1−/− single knock-out 
mice (p-value < 0.05) (Fig. 4a). No significant differences 
in survival were observed between the cohorts of Mbd4−/− 
Mlh1+/+ and wild type, single and double heterozygous 
mice (Fig. 4a).
In keeping with the survival differential, a 
difference in tumor incidence and distribution was 
observed in Mbd4−/− Mlh1−/− double knock-out mice 
compared with Mlh1 single knockout mice (Fig. 4b). 
Specifically, Mbd4−/− Mlh1−/− mice developed 
lymphomas at a higher incidence (83%) than Mlh1−/− 
mice (52%), but this difference was not statistically 
significant (Fisher’s exact test p = 0.35). A detailed 
histological analysis revealed that tumor spectrum 
associated with the Mlh1 defect was modified in 
Table 3: Classification and relationship to MMR status of MBD4 variants
Exon
MBD4 
sequence 
change1
Type and 
number of 
sequence 
changes
Frequency 
in control 
chromosomes 
(%)2,3
Functional 
or 
Interaction 
Domains
Glycosylase 
Assay3
In Silico 
Predictions4 Classification
5
Co-occurrence 
of MMR 
germline 
defect
3
c.811G > A
(p.Ala273Pro)
rs10342
5 germline 
+3 somatic6
8.11
8.11
SIN3a/
HDAC1 ND 4/4 Concordant B
likely non-
pathogenic
MLH1  
(n = 2)
MSH2  
(n = 2)
MSH6  
(n = 1)
c.1024T > C
(p.Ser342Pro)
rs2307289
2 germline 4.316
SIN3a/
HDAC1
slightly 
reduced 4/4 Concordant B VUS
MSH2  
(n = 1)
c.1036G > A
(p.Glu346Lys)
rs140693
2 germline 0.9911
SIN3a/
HDAC1 ND 3/4 Concordant B
likely non-
pathogenic none
c.1073T > C
(p.Ile358Thr)
rs2307298
4 germline 0.860.4
linker 
region ND 4/4 Concordant B
likely non-
pathogenic none
c.1158G > T
(p.Cys386Phe)
1 germline NR linker region
slightly 
reduced 3/4 Concordant P VUS MLH1
5
c.1387 > T
(p.Thr463Ser)
1 germline NR glycosylase domain
markedly 
reduced 3/4 Concordant P
likely 
pathogenic none
c.1400 > G
(p.Asn467Ser)
rs78782061
1 germline 0.170.17
glycosylase 
domain ND Discordant VUS none
8
c.1702G > C
(p.Asp568His)
rs2307293
1 germline 0.440.44
glycosylase 
domain proficient Discordant VUS MLH1
1Novel variants identified in this study are reported in bold
2Minor allele frequencies (MAF) obtained using Exome Variant Server (top number) and 1000 Genomes browser (bottom 
number)
3NR = not reported; ND = not done
4P = pathogenic; B = benign
5VUS = Variant of Unknown Significance
6Of these, one tumor carries a germline MLH1 mutation, one tumor carries a germline MSH2 mutation and one tumor 
carries a germline MSH6 variant of unknown significance.
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double-mutant mice, which developed only high-grade 
lymphomas compared to Mlh1 single knockout mice, 
which most frequently manifested high grade lymphoma 
(52%), but also lymphoid hyperplasia (19%) and other 
tumors (5%) (Fig. 5a–5d).
No significant differences in tumor incidence and 
distribution were found between Mbd4−/− Mlh1+/+ mice 
and the other genotype groups, monitored over a period 
of 30 months. Specifically, lymphomas were identified 
in 30% of Mbd4−/− Mlh1+/+ mice, a frequency marginally 
higher than that of mice with the other genotypes 
(26%). Early lymphomas were found in 20% of Mbd4−/− 
Mlh1+/+ and 4% of Mbd4 wild type, single and double 
heterozygous mice; lymphoid hyperplasia was found 
in 15% and 13% of Mbd4−/− Mlh1+/+ (Fig. 5e–5f) and 
the remaining cohort, respectively. Finally, additional 
pathology findings, including intestinal adenocarcinoma 
(Fig. 5g–5h), were identified in 5% and 22% of Mbd4 
single knockout mice and the remaining genotypes, 
respectively.
Figure 2: Single-turnover thymine glycosylase assays for MBD4 DNA coding variants. Wild-type, p.Ser342Pro, p.Cys386Phe, 
p.Thr463Ser and p.Asp568His recombinant MBD4 proteins were assayed for glycosylase activity. The p.Thr463Ser mutant protein showed 
a marked reduction of thymine glycosylase activity for G:T mismatch (lane 6).
Figure 3: Box-and-whisker plot of the number of C:G > T:A transition mutations in MLH1, MBD4-MMR, MBD4 and 
“WT” CRC groups. In each plot, the height of the box represents the inter-quartile range (IQR) where the upper and lower ends indicate 
the third and first quartiles, respectively. The solid black horizontal line inside the box represents the median value while the whiskers (the 
two solid horizontal lines at either end, connected by dotted lines) extend to the most extreme data points which are no more than 1.5 times 
the IQR from the box in each direction (the points that lie beyond these whiskers are considered to be outliers). Statistical significance of 
the comparisons is as follows: MLH1 vs MBD4: p = 0.0064; MLH1 vs MBD4-MMR: p = 0.0054; MLH1 vs “WT”: p = 0.0027; MBD4 vs 
MBD4-MMR: p = 0.67; MBD4 vs “WT”: p = 1.03 × 10−6; MBD4-MMR vs “WT”: p < 1 × 10−6.
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DISCUSSION
In this study, we first analyzed the frequency, pattern 
and significance of germline/somatic MBD4 sequence 
variants in a large series of human hereditary/familial 
and sporadic CRC patients/tumors, and found that MBD4 
frameshift mutations are only detected in tumors (somatic 
change), whereas missense variants are detected, at lower 
frequency, in both normal and tumor DNA. Evaluation of 
different molecular, in silico and functional parameters 
(including: impaired glycosylase activity, concordance 
of at least three out of four software predictions, and 
frequency in control chromosomes), provided evidence 
on the biological role of 4 out of 8 MBD4 missense 
variants identified in this study. Specifically, one variant 
(p.Thr463Ser) is considered as likely pathogenic and 
the other three variants (p.Ala273Pro, p.Glu346Lys and 
p.Ile358Thr) as likely non-pathogenic. The remaining 4 
missense variants are considered as variants of unknown 
significance (VUS), due to the lack of data available for 
the classification or discrepancies among the parameters 
evaluated here (Table 3).
Based on the glycosylase assay, the p.Thr463Ser 
variant has significantly decreased activity. The 
p.Ser342Pro and p.Cys386Phe variants have slightly 
reduced activity despite not mapping in the glycosylase 
domain; we cannot rule out a possible impact of altered 
protein folding on the pathogenic role of these two 
variants. Recently, biochemical studies have shown that 
MBD4 p.Asp568His mutant protein has reduced catalytic 
activity and binding affinity to DNA [36]. This variant 
showed apparently minimal impact on glycosylase activity 
in our biochemical assay and scored as non-pathogenic in 
two out of four prediction programs (Mutation Assessor 
and SIFT). The reasons for this discrepancy are presently 
unknown.
Our findings indicate that MBD4 inactivation may 
occur not only by expansions/deletions in the polyadenine 
tracks in MSI-H tumors, as previously reported [15–18], 
but also by point mutations in other portions of the coding 
sequence. The occurrence of MBD4 missense changes 
and the higher frequency of MBD4 pathogenic variants 
in CRC genomic data, compared to controls, suggests 
that MBD4 mutations are not only secondary to MSI in 
MMR-deficient tumors, but may occur independently 
and presumably be selected for during tumorigenesis. 
Moreover, we have found that the overall frequency of 
MBD4 mutations in MSI-H tumors (28/102, 27.4%) is 
in the range of the mutation frequencies (19.4–92%) of 
the genes contributing to the mutator phenotype in CRC 
tumorigenesis [37]. Similarly, a maximum likelihood 
method to identify real target genes of MMR also indicated 
that MBD4 frameshift mutations may provide selective 
pressure during CRC tumorigenesis [38]. In a portion 
of our tumors, we found evidence of MBD4 frameshift 
mutations and LOH at its locus on 3q21-q22, suggesting 
biallelic inactivation (Suppl. Fig. 1), as previously 
proposed [17]. All these data support the notion that 
MBD4 defects may further increase genomic instability 
and play a role in colorectal tumorigenesis.
The possibility that MBD4 may act as a mutator 
in intestinal tumorigenesis is confirmed by two studies 
showing that Mbd4 inactivation in reporter BigBlue mice 
leads to a 3-fold increase in mutation frequency, especially 
C > T transition at CpG sites, in the spleen and small 
intestine [31, 32]. This enhanced mutability manifests 
Figure 4: Mbd4 deficiency alters tumorigenesis in Mlh1−/− mouse model. A. Kaplan-Meier analysis of Mbd4−/− Mlh1−/− mice 
(n = 10), Mbd4−/− Mlh1+/+ mice (n = 22) and Mbd4+/+ Mlh1−/− (n = 24) and wild-type, single and double heterozygous mice (n = 122) revealed 
a significant reduction of survival in Mbd4−/− Mlh1−/− mice (p value < 0.05) for the comparison of Mbd4−/− Mlh1−/− mice vs. Mbd4+/+ Mlh1−/− 
mice). B. Mbd4 biallelic inactivation increased lymphoma incidence in Mbd4−/− Mlh1−/− double knockout mice when compared with 
Mlh1−/− single knockout mice, but this difference was not statistically significant by Fisher’s exact test (p = 0.35).
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also as accelerated tumorigenesis due to Mbd4 loss in two 
Apc mutant mouse models [31, 32]. A pathogenic role of 
MBD4 variants and their effect on the tumor mutational 
landscape, possibly consistent with its role in avoiding 
mutability at CpG sites [3, 32, 33], is confirmed by our 
finding of increased frequency of C:G > T:A transitions in 
CRC cases with MBD4 mutation or combined MBD4 plus 
major MMR gene mutations, compared to both CRC cases 
Figure 5: Representative hematoxylin & eosin-stained sections of tumors developed in A-B) Mbd4−/− Mlh1−/−; C-D) 
Mbd4−/− Mlh1+/+ ; E-F) Mbd4+/+ Mlh1−/−; and G-H) Mbd4+/− Mlh1−/− mice. Panels A) and B) show a high-grade lymphoma 
typical of the double mutant mice. Panels C) and D) depict severe lymphoid hyperplasia in the lung characterized by an abundant 
perivascular lymphocytic infiltrate. Panels E) and F) show lymphoid hyperplasia in a lymph node. Panels G) and H) show fields of 
invasive adenocarcinoma of the intestine (note foci of invasion in the muscularis in panel H)). 20X magnification (left panels) and 40X 
magnification (right panels) are shown.
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with MLH1 variants and CRC cases with no mutation in 
MBD4 or major MMR gene (Fig. 3). Future studies will 
have to determine the sequence context of C:G > T:A 
transitions in CRC cases with MBD4 mutation, in order 
to ascertain whether these transitions occur preferentially 
in the context of CpG sites, as predicted on the basis of 
MBD4 anti-mutagenic function. Importantly, C:G > T:A 
transition mutations in the context of CpG sites are the 
most prevalent mutational signature in the vast majority 
of human cancer types, including CRC [39].
Here, we evaluated the contribution of Mbd4 
inactivation on an Mlh1-cancer predisposing background 
in vivo. We found that Mbd4 and Mlh1 double knockout 
mice showed a significant survival reduction and increased 
incidence of high-grade lymphomas compared with Mlh1 
single knockout mice. Noteworthy, our findings differ 
from a previous study, in which biallelic inactivation of 
Mbd4 had no impact on mutation frequency in vivo and 
did not modify the cancer predisposition phenotype in 
mice doubly deficient for Mbd4 and MMR genes [33]. 
This discrepancy could be due to the fact that the targeted 
allele used in the previous study may allow the synthesis 
of a small amount of wild type mRNA [32]. Additionally, 
our data are based on an accurate study of a large number 
of mice (n = 178) compared to the smaller number (n = 
57) included in the previous study [33]. The relatively high 
incidence of lymphoma, early lymphoma and lymphoid 
hyperplasia in Mbd4−/− mice may be due to the role of 
this gene in Immunoglobulin CSR [10]. Consistent with a 
possible pathogenic role, our detailed histological analysis 
revealed that Mbd4 modifies the tumor spectrum associated 
with the Mlh1 defect leading to more aggressive tumors. 
Thus, loss of Mbd4 function confers increased tumor 
susceptibility and a more severe outcome when combined 
with the cancer-predisposing Mlh1−/− background.
Moreover, our results that MBD4 alterations may 
contribute to MMR-deficient tumorigenesis are supported 
by our previous study showing reduction in MMR protein 
levels in Mbd4−/− MEFs [5]. More recently, additional 
evidences have supported the role of MBD4 in CRC 
tumorigenesis. In fact, overexpression of a truncated form 
of MBD4 lacking the glycosylase domain in a BigBlue-
transfected human MSH6-deficient colorectal cancer cell 
line, led to a 2-fold increase in mutation frequency and 
predisposed to chromosomal instability, compared to 
controls [9, 22].
Taken together, our evidence indicates a key role 
for MBD4 as a modifier of tumorigenesis associated 
with MMR mutations, likely by increasing the genomic 
instability phenotype of a subset of MMR-defective 
tumors, specifically contributing to elevated C:G > T:A 
transitions. Our results also suggest that MBD4 mutations 
may be responsible for a worse outcome (based on the 
mouse studies), and possibly resistance to therapy [5, 7], of 
a subset of MMR-deficient tumors. A retrospective analysis 
in a larger series of human samples with MMR and MBD4 
defects may be helpful to confirm the association with the 
more severe outcome observed in our in vivo study.
MATERIAL AND METHODS
Patient selection and MBD4 molecular analysis
This study was performed on sporadic and 
hereditary/familial CRC cases from high-risk patients 
referred for genetic counseling to the following institutions: 
Departments of Medical Genetics and Pathology of the 
University of Helsinki, Centro di Riferimento Oncologico 
of Aviano, Istituto Nazionale Tumori (INT) of Milan, 
Department of Human Genetics of the Leiden University 
Medical Center (LUMC), Josephine Nefkens Institute of 
Erasmus MC of Rotterdam and Department of Medical 
Genetics of the Catholic University of Rome. The presence 
of MMR defects was ascertained by a combination of MSI 
testing, immunohistochemistry for MLH1 and MSH2, 
sequencing and Multiplex ligation-dependent probe 
amplification (MLPA) of MLH1 and MSH2, as previously 
done [17, 40–42]. LOH at the MBD4 locus (3q21-22) in 
tumor DNA was performed as previously described [17]. 
Clinical and histopathogical data were also collected 
during genetic counseling.
A total of 332 hereditary (defined as meeting the 
Amsterdam/Bethesda criteria), familial (partially fulfilling 
the Amsterdam/Bethesda criteria) and sporadic CRC cases 
were selected for MBD4 sequence analysis. Tumors were 
classified as microsatellite stable (MSS) or with MSI-high 
(MSI-H) or -low (MSI-L), according to standard methods 
[43–45]. In this study, we also included 42 tumors 
previously reported [17], re-evaluated for MSI status 
and/or MMR defects. The complete coding sequence and 
flanking exon-intron borders of the MBD4 gene were 
investigated by direct sequencing of PCR products from 
genomic DNA extracted from peripheral blood and fresh 
or paraffin-embedded tumor tissues. Primers and PCR 
conditions are available upon request.
MBD4 variants were defined according to the 
recommendations of the Human Genome Variation 
Society (http://www. hgvs.org/mutnomen/). DNA mutation 
numbering is based on the MBD4 cDNA sequence 
(GenBank accession numbers NM_003925.2) with the 
A of the ATG translation-initiation codon numbered as +1. 
Amino acid numbering starts with the translation initiator 
methionine as +1.
The study was performed in accordance with 
the Declaration of Helsinki (http://www.wma.net/
en/30publications/10policies/b3/index. html). Informed 
consent was obtained from all patients for the use of 
specimens and clinico-pathological data for research 
purposes, according to the guidelines established by the 
local ethical committee.
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The Exome Variant Server (http://evs.gs 
.washington.edu/EVS/) and 1000 Genomes databases 
(www.1000genomes.org/) were used to ascertain the 
frequencies of the MBD4 variants in control populations.
Functional and in silico assays
DNA N-glycosylase assays were performed for 
the following DNA coding variants: p.Ser342Pro, 
p.Cys386Phe, p.Thr463Se and p.Asp568His. Site-directed 
mutagenesis of MBD4 cDNA for the above-mentioned 
DNA variants was carried out using the QuickChange 
mutagenesis kit (Stratagene). Cloning, expression and 
purification of wild type and mutant MBD4 proteins were 
performed as previously described [46, 47]. To determine 
the effect of the MBD4 mutant proteins on the intrinsic rate 
of thymine and uracil removal compared with wild-type 
enzyme, glycosylase assays were carried out under single-
turnover conditions, using a 37-bp duplex containing a 
centrally located G:T mismatch in a CpG context [46, 47].
Putative effects of MBD4 missense variants 
were evaluated at the protein level using PolyPhen-2 
(http://genetics.bwh. harvard.edu/pph2/) [48], SIFT 
(http://sift.jcvi.org/) [49], Mutation Taster (http://www.
mutationtaster.org/) [50] and Mutation Assessor (http://
mutationassessor.org) [51].
The frequency of C:G > T:A transition mutations 
was evaluated in four series of CRC samples selected 
from the COSMIC dataset v72 [34]: i) tumors with MBD4 
pathogenic (splicing, truncating and nonsense) variants 
(n = 7); ii) tumors with MBD4 variants plus variants in one 
of the major MMR genes (i.e. MLH1, MSH2 and MSH6) 
(n = 5); iii) tumors with pathogenic (splicing, truncating 
and nonsense) MLH1 variants (n = 11); tumors with no 
MBD4 or MMR variants (n = 12).
Generation of Mbd4−/− Mlh1−/− double 
mutant mice
The Mbd4 Δ2–5 mutant mice used in this study 
were generated by targeted deletion of exons 2–5 and 
are null for both 5mC binding and glycosylase activity 
[5]. Mbd4+/− mice were mated with Mlh1+/− mice [35] to 
generate F1 double heterozygotes (Mbd4
+/− Mlh1+/−); both 
strains have a C57BL/6 genetic background. F1 double 
heterozygotes were interbred to generate F2 mice with 
experimental and control genotypes: Mbd4−/− Mlhl−/−, 
Mbd4+/+ Mlhl−/−, Mbd4−/− Mlhl+/+ and Mbd4+/+ Mlhl+/+ 
mice. Animal protocols and all the procedures of mouse 
handling were approved by the Institutional Animal Care 
and Use Committee of the Fox Chase Cancer Center.
Histopathological and tumor incidence analyses
Animals were sacrificed at the first development of 
signs of distress or when tumor growth became apparent. 
Tumors and other organs (including spleen, lymph nodes, 
GI tract and liver) were embedded in paraffin, and sections 
were stained with hematoxylin/eosin. A total of 178 mice, 
divided in four cohorts based on genotypes (Mbd4−/− Mlhl−/−, 
Mbd4+/+ Mlhl−/−, Mbd4−/− Mlhl+/+ and a cohort of wild type, 
single or double heterozygotes together), were included in 
this study and the incidence and the spectrum of tumors 
were evaluated. A Kaplan-Meier analysis was performed to 
plot the overall survival of the mice. Statistical significance 
was measured using the log-rank test.
Statistical methods
COSMIC dataset v72 [28], cBioPortal [29] and 
Exome Variant Server (http://evs.gs.washington.edu/
EVS/) data were also used to ascertain the frequency of 
MBD4 pathogenic and likely non-pathogenic variants 
in colorectal cancer tumors and controls. Fisher’s exact 
test and a binomial test of proportions were used to 
compare the frequency of MBD4 pathogenic and likely 
non-pathogenic changes in tumor and control samples. 
Both tests were two-sided with a Type I Error of 0.05 to 
determine statistical significance.
Fig. 3 displays the distribution of the number of 
C > T substitutions in four series of CRC samples (see 
above): MLH1, MBD4-MMR, MBD4 and “wild type 
(WT)” control (no MBD4 or MMR gene mutations). In 
order to account for over-dispersion in counts, a quasi-
Poisson model was used to compare the mean number 
of C > T substitutions between MBD4-MMR and MBD4, 
MBD4-MMR and WT, MBD4-MMR and MLH1, MLH1 
and MBD4, and between MLH1 and WT. Fisher’s exact 
test was used to compare the incidence of lymphomas 
between Mbd4−/− Mlh1−/− and Mbd4+/+ Mlh1−/− mice. All 
tests were two-sided and a Type I Error of 0.05 was used 
to determine statistical significance.
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